Abstracts tagged "Vasculitis"

Abstract Number: 1612 • ACR Convergence 2025
Window of opportunity with tocilizumab therapy in giant cell arteritis. Multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Diana Prieto-Peña³, Vicente Aldasoro Cáceres⁴, Olga Maiz⁵, Eugenio de Miguel⁶, Eva Galíndez Agirregoikoa⁷, Ivan Ferraz Amaro⁸, Santos Castañeda⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁵Hospital Universitario de Donosti, Donostia, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biological drug currently approved for the treatment of giant cell arteritis (GCA), regardless of GCA duration. The “window of…
Abstract Number: 1882 • ACR Convergence 2025
Vessels Under Fire: National Mortality Trends in Systemic Vasculitides in the United States, 1999–2020
Aziz-ur-Rahman Khalid¹, Ghassan Makhoul², Hasan Munshi², Islam Rajab², Emmanuel Olumuyide³, MD Walid Akram Hussain², Ahmed Huzien² and Robert Lahita⁴, ¹St. Joseph's University Medical Center, wayne, ²St. Josephs University Medical Center, Paterson, ³Advocate Illinois Masonic Medical Center, Chicago, ⁴St. Josephs University Medical Center, Wayne, NJ
Background/Purpose: Systemic vasculitides are rare but potentially life-threatening inflammatory disorders affecting blood vessels. Despite therapeutic advances, national mortality trends across vasculitis subtypes remain poorly defined.…
Abstract Number: 2538 • ACR Convergence 2025
Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease
Rafael Gálvez Sánchez¹, José Luis Martín-Varillas², Lara Sánchez Bilbao³, Ivan Ferraz Amaro⁴, Carmen Lasa Teja⁵, Elena Aurrecoechea⁶, Diana Prieto-Peña⁷ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ⁶Hospital Sierrallana, CANTABRIA, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain
Background/Purpose: Behçet´s Disease (BD) was traditionally classified according to the International Study Group (ISG) in which oral ulcers were mandatory. International Team for the Revision…
Abstract Number: 0238 • ACR Convergence 2025
Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
Alessia Gatti¹, Francesca Regola¹, Giulia Fontana², Jacopo Mora², Mario Andrea Piga³, Gianluca Moroncini³, Rossella Acquaviva⁴, Palma Carlucci⁴, Silvia Noviello⁴, Angelo Vacca⁴, Paolo Delvino⁵, Enrico Heffler⁶, Emanuele Nappi⁶, Jakub Moll⁷, Jan Schroeder⁷, Laura Losappio⁷, Federica Davanzo⁸, Roberto Padoan⁹, Paolo Cameli¹⁰, Edoardo Conticini¹¹, Greta Pacini¹², Alvise Berti¹², Lorenzo Vrola¹³, Paola Tomietto¹³, Benedetta Fazzi¹⁴, elena treppo¹⁵, Luca Quartuccio¹⁴, Jan Willem Cohen Tervaert¹⁶, Sabrina Arnold¹⁷, Prof. Dr. med. Peter Lamprecht¹⁸, Florence Roufosse¹⁹, Ilaria Cavazzana¹, Franco Franceschini²⁰, Giacomo Emmi²¹ and Paola Toniati²², ¹Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ³Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, ⁴Section of Internal Medicine 'Guido Baccelli', Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari, Italy, ⁵Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy, ⁶Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI) and Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milano, Italy, ⁷Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milano, Italy, ⁸Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, ⁹Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ¹⁰University of Siena, Siena, Italy, ¹¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ¹²Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy, ¹³UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, ¹⁴Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, ¹⁵Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ¹⁶University of Alberta, Edmonton, AB, Canada, ¹⁷Department of Rheumatology and Clinical Immunology, University of Lübeck, Lubeck, Germany, ¹⁸University of Lübeck, Lübeck, Germany, ¹⁹Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Bruxelles, Belgium, ²⁰University of Brescia, Brescia, Brescia, Italy, ²¹Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy, ²²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy
Background/Purpose: Eosinophilic gastrointestinal disorders (EGIDs) are a group of disorders characterized by marked eosinophilic infiltration of the gastrointestinal (GI) tract resulting in organ dysfunction and…
Abstract Number: 0750 • ACR Convergence 2025
Fibrinogen as a biomarker in the diagnosis of giant cell arteritis and detection of flares
Jonathan Miller¹, Sharon Cowley², Patricia Harkins³, David O'Sullivan⁴, Gearoid McGeehan⁵, Eamonn Molloy⁶, Richard Conway⁷, David Kane⁸ and Geraldine mcCarthy⁹, ¹St Vincent's University Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³Trinity College Dublin, Dublin ⁸, Dublin, Ireland, ⁴Tallaght University Hospital, Dublin, Dublin, Ireland, ⁵Mater Misericordiae University Hospital, Dublin, Dublin, Ireland, ⁶St Vincent's University Hospital, Dublin, Dublin, Ireland, ⁷Trinity College Dublin, Dublin, Dublin, Ireland, ⁸Tallaght University Hospital & Trinity College Dublin, D²⁴, Dublin, Ireland, ⁹Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the commonest idiopathic systemic vasculitis in adults over 50 years of age. It can be associated with high morbidity.…
Abstract Number: 0719 • ACR Convergence 2025
A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis
Ivana Stojkic¹, Arnon Arazi², Huijuan Song³, Pearlly Yan³, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Brad Rovin⁴, Stacy Ardoin¹ and Salem Almaani³, ¹Nationwide Children's Hospital, Columbus, OH, ²The Feinstein Institutes for Medical Research, Manhasset, ³OSU, Columbus, OH, ⁴The Ohio State University, Columbus, OH
Background/Purpose: ANCA-associated vasculitis frequently involves the kidneys causing glomerulonephritis (AAGN). Despite advances in treatment, many patients develop end-stage kidney disease. An improved understanding of the…
Abstract Number: 1613 • ACR Convergence 2025
Switching From Reference Tocilizumab to Biosimilar in Giant Cell Arteritis: Effectiveness and Safety in a Multicenter Study of 38 Patients
Adrian Martin-Gutierrez¹, Fernando Lopez Gutierrez², Javier Loricera³, Juan Molina-Collada⁴, Juan Carlos Nieto⁵, Marina Sánchez-Lucas⁶, Maite silva⁷, Patricia Moya Albarado⁸, Eztizen Labrador-Sanchez⁹, Ivan Ferraz Amaro¹⁰ and Ricardo Blanco¹¹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain, ⁷Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, Galicia, Spain, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹Hospital Universitario San Pedro, Laguardia, Spain, ¹⁰Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: The cost of original biologics may limit treatment access. Biosimilars are biologics that are structurally highly similar and functionally equivalent to the approved reference…
Abstract Number: 1912 • ACR Convergence 2025
Cutaneous manifestations of vasculitis: A cross-sectional analysis from an international cohort
Robert Micheletti¹, William Song¹, Brian Chu², Lynne Allen-Taylor³, Joel Gelfand³, Peter Grayson⁴, Cristina Ponte⁵, Joanna Robson⁶, Ravi Suppiah⁷, Raashid Luqmani⁸, Richard Watts⁹ and Peter Merkel¹⁰, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Brown University Health, Providence, RI, ³University of Pennsylvania, Philadelphia, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁵Unidade Local de Saúde de Santa Maria, Lisbon, Portugal, ⁶University of the West of England Bristol, Bristol, United Kingdom, ⁷Health New Zealand - Te Toka Tumai, Auckland, New Zealand, ⁸University of Oxford, Oxford, United Kingdom, ⁹University of East Anglia, Norwich, United Kingdom, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: Vasculitis is a group of rare, multisystem diseases which may involve the skin. Characterization of the frequency, type, and significance of cutaneous manifestations in…
Abstract Number: 2542 • ACR Convergence 2025
A Rule Based NLP Pipeline for Glucocorticoid exposure
Simran Nimal¹, Megan Sullivan¹, Christopher Conyers², Joseph Rosen¹, Christopher Grilli¹, Kenneth Warrington³ and Victor E Ortega¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic Arizona, Scottsdale-⁸⁵²⁵⁹, AZ, ³Mayo Clinic, ROCHESTER, MN
Background/Purpose: Glucocorticoids (GCs) are essential for managing giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), but prolonged use poses risk due to cumulative dosing and…
Abstract Number: 0251 • ACR Convergence 2025
Impact of Mepolizumab on Idiopathic Hypereosinophilic Syndromes: Preliminary Analysis of a Monocentric Retrospective Cohort
Jacopo Mora¹, Francesca Regola¹, Paola Toniati², Giulia Fontana¹, Alessia Gatti¹, Ilaria Cavazzana³ and Franco Franceschini⁴, ¹Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy, ³Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Lombardia, Italy, ⁴University of Brescia, Brescia, Brescia, Italy
Background/Purpose: Idiopathic hypereosinophilic syndromes (iHES) are a group of disorders characterized by persistent eosinophilia and eosinophil-mediated organ damage. Mepolizumab, an anti-interleukin-5 monoclonal antibody, has proven…
Abstract Number: 0752 • ACR Convergence 2025
Characterization of patients with polymyalgia rheumatica in the ARTESER giant cell arteritis cohort
Maite Silva-Diaz¹, Marta Domínguez-Álvaro², Rafael B. Melero-González³, Elisa Fernández-Fernández⁴, Jesús Alejandro Valero⁵, Ismael González⁶, Julio Sánchez Martín⁷, Javier Narváez⁸, Eva Galíndez Agirregoikoa⁹, Vicente Aldasoro Cáceres¹⁰, lydia Abasolo Alcazar¹¹, Javier Loricera¹², Noemí Garrido¹³, Santos Castañeda¹⁴, Carlota L Iñiguez¹⁵, Alicia Garcia¹⁶, Clara Molina Almela¹⁷, María Alcalde Villar¹⁸, Antonio Juan Mas¹⁹ and Ricardo Blanco²⁰, ¹Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Hospital Universitario Donosti, Donosti, Spain, ⁶Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁷Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁰Hospital Universitario de Navarra, Pamplona, Spain, ¹¹IdISSC. HCSC, Madrid, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ¹⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁵Hospital del Bierzo, Ponferrada, Castilla y Leon, Spain, ¹⁶Rheumatologist, La Laguna, Spain, ¹⁷Consorci Hospital General Universitari de València, Valencia, Spain, ¹⁸Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is a chronic granulomatous vasculitis affecting medium- and large-sized arteries (1). The classic symptoms are cranial symptoms, including headache, jaw…
Abstract Number: 0894 • ACR Convergence 2025
Altered B cell subpopulations in Giant Cell Arteritis
Maria-Eugenia Miranda-Carus¹, Beatriz Nieto-Carvalhal², Irene Monjo Henry¹, Sara García-Carazo³ and Eugenio de Miguel¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Universitario La Paz, Mdrid, ³Hospital La Paz, Madrid
Background/Purpose: Giant cell arteritis (GCA), a large-vessel granulomatous vasculitis, has been considered as a T cell-dependent condition. Interestingly, tertiary lymphoid structures, B cell and plasma…
Abstract Number: 1614 • ACR Convergence 2025
A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
Alice Bartoletti¹, Georgina Ducker², Mrinalini Dey³, Durga Prasanna Misra⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Department of Rheumatology, ASST Gaetano Pini CTO, Milan, Italy, Milan, Lombardia, Italy, ²Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ³Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK, London, England, United Kingdom, ⁴Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) date back to 2015…
Abstract Number: 1931 • ACR Convergence 2025
COSMOS Prevalence of aTTP in SLE
Nisha Sapkota¹, Yevheniia Andriushchenko², Saadia Malik², Sarang Choi² and Sima Terebelo², ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse manifestations, including thrombotic thrombocytopenic purpura (TTP), a life-threatening hematologic disorder. The pathogenesis of…
Abstract Number: 2543 • ACR Convergence 2025
Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods
Mustafa Erdogan¹, Koray Tascilar², Yagmur Ersoya³, Alp Ozcan⁴, Mert Gurcan⁴, Talal Ammar⁴, Sinem Nihal Esatoglu⁵, Yesim Ozguler⁵, Gulen Hatemi⁵ and Hasan Yazici⁶, ¹Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Division of Rheumatology / Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Friedrich Alexander University of Erlangen Nuremberg, Universitätsklinikum Erlangen Department of Medicine ³, Rheumatology and Immunology, Erlangen, Germany, ³Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁶Academic Hospital, Istanbul, Turkey
Background/Purpose: There is consensus that the visual prognosis in Behçet syndrome (BS) uveitis has considerably improved in time (1-3). We wanted to better quantitate this…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].